Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFusion Antibody Share News (FAB)

Share Price Information for Fusion Antibody (FAB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.85
Bid: 3.80
Ask: 3.90
Change: 0.00 (0.00%)
Spread: 0.10 (2.632%)
Open: 3.85
High: 3.85
Low: 3.85
Prev. Close: 3.85
FAB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Omega Diagnostics Signs Contract To Make Covid Tests; Appoints Chair

Thu, 11th Feb 2021 11:16

(Alliance News) - Omega Diagnostics Group PLC said Thursday it has agreed a contract with the UK Department of Health & Social Care to provide manufacturing capacity for Covid-19 lateral flow antigen tests.

Shares in the medical diagnostics product distributor and manufacturer were 4.3% higher in London on Thursday mid-morning at 96.95 pence each.

"The intention is that as soon as the DHSC has access to a test that has successfully passed a performance evaluation, the test will be licensed for Omega to manufacture. As part of the contract, DHSC will loan a number of key pieces of manufacturing equipment," Omega said.

The firm noted this will allow it to expand production at its Alva-based facility.

Omega said it expects to be able to produce about 2 million tests per week by the end of April, when combining the government-loaned equipment with its own manufacturing equipment.

"Omega expects that this capacity will be sufficient to meet the expected demand for lateral flow Covid-19 antigen tests, with enough remaining capacity to be used for Visitect CD4 or Covid-19 antibody tests according to demand," the company said.

Omega expects a "significant contribution" from the government contract to boost its financial year ending March 31, 2022, but noted it is too close to the end of financial 2021 to have any impact.

"For the current financial year ending March 31, 2021, the company's Food Intolerance division has held up well, despite the impact from pandemic lasting longer than originally thought," Omega said.

Sales are expected to be in the region of GBP7.5 million for financial 2021, which is a 19% year on year drop.

"The board is encouraged by this performance given that food intolerance sales in the first quarter of this financial year were 47% down over the first quarter of the prior year," Omega added.

Revenue from Covid-19 products and contracts is expected to be about GBP1.5 million which includes sales from the UK-RTC antibody test, sales of the Mologic ELISA antibody test and development income for work undertaken on behalf of a third party.

Total revenue is expected to be about GBP9.3 million, with an earnings before interest, taxes, depreciation and amortization loss between GBP2.1 million and GBP2.3 million.

"Despite the considerable investment in the scaling-up of our production capacity, the year-end cash position is expected to be in the region of GBP5.5 million to GBP6.0 million," Omega added.

Chief Executive Colin King said: "We are delighted to formalise our relationship with the UK government and to utilise our lateral flow test production capacity to support the Covid-19 mass testing programme being rolled out across this country. I appreciate that trading in our core business has been softer than expected for the current financial year, however the on-going opportunity for growth in CD4 testing and Food Intolerance revenues is unchanged.

"The new financial year will see this growth opportunity realised, and will also see the full impact of Covid-19 antigen testing, and so we are likely to deliver substantial revenue growth compared to this financial year which ends next month. These are very exciting times for the business and I am delighted that we can play a part in supporting the UK government's national effort to control the spread of the coronavirus."

Separately, Omega has appointed Simon Douglas as independent non-executive chair, with immediate effect.

Douglas has 25 years of board level experience at both early stage and public businesses within the diagnostics, life science and biopharma industries, Omega said.

He is currently non-executive chair of AIM-listed Fusion Antibodies PLC, having previously served as its chief executive officer up until 2011. Douglas is also non-executive chair of C-Major Medical, a private limited company.

As a result of the appointment, Bill Rhodes has stepped down from his position as interim non-executive chair with immediate effect, but he remains on the company's board.

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
27 Feb 2024 14:18

TRADING UPDATES: Sondrel wins USD23 million contract

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
27 Feb 2024 13:15

Fusion Antibodies gets first order under new services agreement

(Sharecast News) - Fusion Antibodies announced the receipt of its first purchase order under a master services agreement on Tuesday, which it agreed with a prominent diagnostics company on 14 February.

Read more
14 Feb 2024 12:52

Fusion Antibodies raises £1.38m as it seeks new customers

(Sharecast News) - Pre-clinical antibody specialist Fusion Antibodies announced a conditional fundraising of £1.38m before expenses on Wednesday, to help it target mo re industry conferences and customers and generate further supporting data.

Read more
14 Feb 2024 11:27

IN BRIEF: Fusion Antibodies raises GBP1.4 million via placing

Fusion Antibodies PLC - Belfast-based contract researcher, which provides discovery, design and optimisation services for therapeutic antibodies to the healthcare market - Conditionally raises GBP1.4 million before expenses via placing of 34.4 million shares at 4 pence each. The issue price represents a discount of 5.9% to Fusion's closing mid-market share price on Tuesday. Further, it intends to issue 1.5 million new shares to certain directors in lieu of or in satisfaction of salary and fees due to them and which shall be issued immediately following publication of its announcement. Also intends to grant a total of up to 3.8 million new share options to staff and senior management.

Read more
6 Feb 2024 11:48

Fusion Antibodies strikes follow-on research and development project

(Alliance News) - Fusion Antibodies PLC on Tuesday said it has won a follow-on project under a collaborative research and development agreement with an unnamed "US-based biotechnology company".

Read more
6 Feb 2024 10:05

AIM WINNERS & LOSERS: Beeks Financial Cloud is ahead of expectations

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
1 Feb 2024 16:27

Fusion Antibodies confirms £0.28m tax credit

(Sharecast News) - Preclinical antibody discovery specialist Fusion Antibodies announced the successful receipt of a research and development tax credit from HMRC on Thursday.

Read more
1 Feb 2024 12:00

Fusion Antibodies gets tax credit from UK HMRC for OptiMAL platform

(Alliance News) - Fusion Antibodies PLC on Thursday announced the receipt of a research & development tax credit from UK HM Revenue & Customs for work performed on the development of its OptiMAL platform and other projects in bioinformatics.

Read more
4 Dec 2023 16:56

LONDON MARKET CLOSE: FTSE 100 slips as miners hold down index

(Alliance News) - Stock prices in London closed lower on Monday, with miners and oil firms holding down the FTSE 100 index.

Read more
4 Dec 2023 12:01

Fusion Antibodies revenue falls, losses widen in first half

(Sharecast News) - Contract research organisation Fusion Antibodies reported first-half revenue of £0.54m on Monday, down from £1.9m a year earlier.

Read more
4 Dec 2023 10:23

AIM WINNERS & LOSERS: Cornerstone FS to beat 2023 expectations

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
4 Dec 2023 10:22

Fusion Antibodies shares fall with revenue despite "positive" outlook

(Alliance News) - Fusion Antibodies PLC on Monday reported a widened loss and reduced revenue for its latest half year, but said its growth prospects are "increasingly positive".

Read more
28 Nov 2023 12:09

Fusion Antibodies shares up on deal with US National Cancer Institute

(Alliance News) - Fusion Antibodies PLC on Tuesday said it has signed a collaboration agreement with the US National Cancer Institute to use its OptiMAL product to discover novel antibodies to treat certain targets.

Read more
28 Nov 2023 10:33

AIM WINNERS & LOSERS: Totally swings to half-year loss on NHS blow

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
9 Nov 2023 12:54

EARNINGS AND TRADING: Wincanton profit down; James Cropper ups payout

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.